TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8769499

Group type: COMPARATOR
Intervention: Nasal CPAP (C1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: No CPAP (C2)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: No CPAP (AP2)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Nasal CPAP (C2)
Number of subjects: 6
Study: 1564128

Group type: EXPERIMENTAL
Intervention: Once-a-day therapy (i.v. dose: 0.8-33 mg/kg; oral dose: 1.6-66 mg/kg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Twice-a-day therapy (i.v. dose: 0.8-33 mg/kg; oral dose: 1.6-66 mg/kg)
Number of subjects: 69
Study: 3544957

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (0.4 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intramuscular buprenorphine (0.3 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intramuscular meperidine (75 mg)
Number of subjects: 54
Study: 29500030

Group type: EXPERIMENTAL
Intervention: Palivizumab for RSV immunoprophylaxis
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study: 27265813

Group type: EXPERIMENTAL
Intervention: Barriers to discussions about end-of-life care
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Facilitator - having had family/friends who died
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Facilitator - concerns about future quality of life
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Facilitator - worries about being a burden on friends/family
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 473
Study: 24462230

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Escitalopram plus CBT
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (nonresponders)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Whole-brain analysis
Number of subjects: 82
Study: 22891236

Group type: EXPERIMENTAL
Intervention: Systematically developed order set
Number of subjects: 7

Group type: COMPARATOR
Intervention: Historical control (ad hoc developed order set)
Number of subjects: 7
Study: 20955603

Group type: EXPERIMENTAL
Intervention: Individualized, nutritional treatment with energy- and protein-rich supplementation
Number of subjects: 124

Group type: COMPARATOR
Intervention: Routine nutritional care (control)
Number of subjects: 124
Study: 18565087

Group type: EXPERIMENTAL
Intervention: Emotional faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upright emotional faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face stimuli
Number of subjects: 0
Study: 16646970

Group type: EXPERIMENTAL
Intervention: One lottery scratch ticket worth 20 Norwegian kroner
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Two lottery scratch tickets
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Two scratch tickets promised if replied within one week
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: 50 kroner banknote
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control group (no incentive)
Number of subjects: 1500
Study: 14653300

Group type: EXPERIMENTAL
Intervention: bleaching with gel + 10% sodium ascorbate (SA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: bleaching with gel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: bleaching with sol + 10% sodium ascorbate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: bleaching with gel + 10% butylhydroxyanisole (BHA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: bleaching with sol + 10% BHA
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: bleaching with gel + immersed in artificial saliva for seven days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: bleaching with sol + immersed in artificial saliva for seven days
Number of subjects: 90

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 90
Study: 10995148

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 74
Study: 7763124

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (2 mg/kg) and intravenous saline (5 mL/kg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intranasal saline (2 mL) and intravenous 10% ethanol (5 mL/kg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (2 mg/kg) and intravenous 10% ethanol (5 mL/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intranasal (2 mL) and intravenous (5 mL/kg) saline
Number of subjects: 34
Study: 2106127

Group type: EXPERIMENTAL
Intervention: Furosemide treatment with high phosphorus intake (1.64 +/- 0.06 mmol/kg per day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Furosemide treatment with moderate phosphorus intake (1.24 +/- 0.02 mmol/kg per day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Furosemide treatment with low phosphorus intake (0.91 +/- 0.06 mmol/kg per day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Furosemide treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not treated with furosemide) with moderate phosphorus intake (1.24 +/- 0.02 mmol/kg per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not treated with furosemide) with low phosphorus intake (0.91 +/- 0.06 mmol/kg per day)
Number of subjects: 16
Study: 509829

Group type: COMPARATOR
Intervention: Hypertonic glucose (A)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Methylprednisolone (B)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 64
Study: 31985602

Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.1 mmol/kg body weight)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Gadoteridol (0.1 mmol/kg body weight)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Gadoterate meglumine (0.1 mmol/kg body weight)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All GBCAs
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gadobutrol
Number of subjects: 15
Study: 30720556

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 342

Group type: COMPARATOR
Intervention: Control
Number of subjects: 342
Study: 28070861

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 2010

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2010
Study: 26054881

Group type: EXPERIMENTAL
Intervention: Ubiquinol‐10 (300 mg per day for 48 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (for 48 weeks)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ubiquinol‐10 (300 mg per day for 96 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (for 96 weeks)
Number of subjects: 28
Study: 23810276

Group type: EXPERIMENTAL
Intervention: Rosuvastatin/olmesartan 20/40 mg (test formulation)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg and olmesartan 40 mg (reference formulation)
Number of subjects: 58
Study: 21592475

Group type: EXPERIMENTAL
Intervention: Lamivudine in the third trimester and postpartum antiviral treatment
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Postpartum lamivudine (n = 16) or entecavir (n = 10)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (standard treatment only)
Number of subjects: 70
Study: 19848566

Group type: EXPERIMENTAL
Intervention: Tailored feedback based on cholesterol-related knowledge, attitudes, beliefs, and perceived barriers to medication adherence; 2 additional tailored IVR support calls.
Number of subjects: 497

Group type: COMPARATOR
Intervention: Generic feedback and a generic cholesterol guide.
Number of subjects: 497
Study: 16964510

Group type: EXPERIMENTAL
Intervention: Skin biopsy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Blood culture
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CSF culture
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combined culture and Gram stain
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 43
Study: 15090314

Group type: EXPERIMENTAL
Intervention: Standard heparin
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (low-molecular-weight dextran)
Number of subjects: 103
Study: 10859723

Group type: EXPERIMENTAL
Intervention: Catheter-based radiation with Ir-192
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 9303024

Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Number of subjects: 54
Study: 8251027

Group type: EXPERIMENTAL
Intervention: DL473 twice‐weekly (2HE+L2/7H2L2)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: ARFp twice‐weekly (2HE+R2/7H2R2)
Number of subjects: 267

Group type: COMPARATOR
Intervention: BRFP daily (2HRE/7HR)
Number of subjects: 267
Study: 2883223

Group type: EXPERIMENTAL
Intervention: Oxytetracycline lavage alone
Number of subjects: 84

Group type: COMPARATOR
Intervention: Oxytetracycline lavage plus peroperative intravenous metronidazole and cefuroxime
Number of subjects: 84
Study: 29265793

Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac 75 mg + thiocolchicoside 4 mg (FDC)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Separate injection of diclofenac and thiocolchicoside (reference)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Both test and reference treatments
Number of subjects: 223
Study: 26250745

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Expressive Writing
Number of subjects: 236

Group type: COMPARATOR
Intervention: Waiting-list Control
Number of subjects: 236
Study: 23878833

Group type: EXPERIMENTAL
Intervention: 9.5% hydrofluoric acid (HF) conditioning
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tribochemical silica coating (TS) conditioning
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (unconditioned)
Number of subjects: 45
Study: 23737940

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg zinc plus riboflavin 0.5 mg/day)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo (riboflavin 0.5 mg/day)
Number of subjects: 324
Study: 20568431

Group type: EXPERIMENTAL
Intervention: Embedding thread at Shenshu (BL 23)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 70
Study: 18802808

Group type: EXPERIMENTAL
Intervention: Doctor's consultation (Group 2 and Group 3)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Phototest (Group 3)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Letter feedback (Group 1)
Number of subjects: 308
Study: 16631127

Group type: EXPERIMENTAL
Intervention: 0.5 mg of alprazolam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1 mg of alprazolam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50 mg of diphenhydramine (Benadryl)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High dose of alprazolam (1 mg)
Number of subjects: 16
Study: 12847155

Group type: EXPERIMENTAL
Intervention: AN1792 (aggregated Abeta42)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 10333379

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg QD)
Number of subjects: 24
Study: 8596376

Group type: EXPERIMENTAL
Intervention: CGP 39393 (10 mg)
Number of subjects: 1119

Group type: EXPERIMENTAL
Intervention: CGP 39393 (15 mg)
Number of subjects: 1119

Group type: EXPERIMENTAL
Intervention: CGP 39393 (20 mg)
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Heparin (5000 IU three times daily)
Number of subjects: 1119
Study: 1822255

Group type: EXPERIMENTAL
Intervention: Atropine (bolus dose 10 micrograms x kg‐1 followed by a constant-rate infusion of 0.02 microgram x kg‐1 x min‐1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Higher dose of atropine (approximately 1.8‐1.9 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cholinergic blockade
Number of subjects: 9
Study: 7077022

Group type: EXPERIMENTAL
Intervention: Group I ('helped') - extensive assistance in completing the task
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Group II ('encouraged only') - verbal encouragement but minimal assistance
Number of subjects: 72

Group type: COMPARATOR
Intervention: Group III ('no contact') - control group with no training sessions
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Group I ('helped')
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Group II ('encouraged only')
Number of subjects: 72
Study: 29688760

Group type: EXPERIMENTAL
Intervention: Antioxidant-enriched multivitamin
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control multivitamin without antioxidant enrichment
Number of subjects: 73
Study: 27352882

Group type: EXPERIMENTAL
Intervention: Melbourne InFANT Program intervention promoting recommended feeding practices
Number of subjects: 542
Study: 25232265

Group type: EXPERIMENTAL
Intervention: Aliva prebiotic (0.5-2 ounces diluted in ORS)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Aliva prebiotic
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (2 ounces diluted in ORS)
Number of subjects: 300
Study: 22309507

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% 0.4 ml · kg(‐1) plus clonidine 1 μg · kg(‐1) in 1 ml (RC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ropivacaine 0.2% 0.4 ml · kg(‐1) plus saline in 1 ml (RS)
Number of subjects: 60
Study: 20235224

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 5604

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 5604

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 5604

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers and cardiac glycosides
Number of subjects: 5604

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 5604

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 5604

Group type: EXPERIMENTAL
Intervention: Amiodarone or Sotalol
Number of subjects: 5604
Study: 17667496

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus followed by 2 mg/min infusion for 4 hours postoperatively)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16148557

Group type: EXPERIMENTAL
Intervention: Oral norfloxacin (25 patients)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin/sulbactam (21 patients)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cirrhotic patients with variceal bleeding
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cirrhotic patients admitted for other reasons
Number of subjects: 94
Study: 12166344

Group type: EXPERIMENTAL
Intervention: Niceritrol 750‐1500 mg/day + Pravastatin 10 mg/day (after 8 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Pravastatin 10 mg/day + Niceritrol 750‐1500 mg/day (after 8 weeks)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combination therapy (Niceritrol + Pravastatin)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Pravastatin alone
Number of subjects: 62
Study: 9565385

Group type: EXPERIMENTAL
Intervention: Personal recommendation from one of the investigators
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Recommendation plus an easy‐to‐read National Cancer Institute (NCI) brochure
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Recommendation, brochure, and a 12‐minute interactive educational and motivational program
Number of subjects: 445

Group type: COMPARATOR
Intervention: Recommendation alone
Number of subjects: 445

Group type: COMPARATOR
Intervention: Recommendation with brochure
Number of subjects: 445
Study: 8292907

Group type: EXPERIMENTAL
Intervention: Cocos nucifera pollen extract immunotherapy (CPE‐IT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 96
Study: 3052814

Group type: COMPARATOR
Intervention: d-fenfluramine (30 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (single dose of 0, 30, 40, and 60 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29297195

Group type: EXPERIMENTAL
Intervention: CPRMeter (feedback group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard non-feedback CPR (non-feedback group)
Number of subjects: 50
Study: 27356644

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Treg (Regulatory cells) in all sedation groups (midazolam, propofol, dexmedetomidine)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treg after 3 ICU days in dexmedetomidine group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treg after 5 ICU days in propofol group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treg after 5 ICU days in midazolam group
Number of subjects: 45
Study: 24796047

Group type: EXPERIMENTAL
Intervention: Acupuncture at Taichong (LR 3), Zusanli (ST 36), and Sanyinjiao (SP 6), once a day, 5 times per week for 4 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Medication group treated with pinaverium (50 mg, 3 times a day) and live combined bifidobacterium and lactobacillus tablet (4 tablets, 3 times a day) for 4 weeks
Number of subjects: 57
Study: 22621163

Group type: EXPERIMENTAL
Intervention: Adper™ Single Bond Plus (SB)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Adper™ Scotchbond SE (SE)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both adhesive systems (SB and SE)
Number of subjects: 97
Study: 20418692

Group type: EXPERIMENTAL
Intervention: Cumulative duration of low BIS (BIS < 45)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Volatile anesthetic concentration
Number of subjects: 460
Study: 18208917

Group type: EXPERIMENTAL
Intervention: Ketamine (n=13)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Opioids (n=24)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-opioid analgesics (n=13)
Number of subjects: 50
Study: 15870609

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% + Pilocarpine (2%, 4%, 6%)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pilocarpine (2%, 4%, 6%)
Number of subjects: 17
Study: 12697633

Group type: EXPERIMENTAL
Intervention: Ertapenem, 1 g once a day
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam, 3.375 g every 6 h
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Ceftriaxone, 1 g once a day
Number of subjects: 1167
Study: 12536743

Group type: COMPARATOR
Intervention: FU (1 mg.kg‐1) combination with sham infusion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: FU (1 mg.kg‐1) combination with 50 ml of 20% solution of Albumin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: FU (1 mg/kg) combination with 250 ml dextran 40
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: FU (1 mg.kg‐1) combination with Albumin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: FU (1 mg/kg) combination with dextran 40
Number of subjects: 18
Study: 9154895

Group type: EXPERIMENTAL
Intervention: 0.12 ppm ozone for 2 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Filtered air for 2 hours
Number of subjects: 12
Study: 8355942

Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream 2% (5 g intravaginally at bedtime for 7 days)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Metronidazole 500 mg (two 250-mg capsules orally twice a day for 7 days)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream 2%
Number of subjects: 407

Group type: COMPARATOR
Intervention: Metronidazole 500 mg
Number of subjects: 407
Study: 3549923

Group type: EXPERIMENTAL
Intervention: 400 mg of berberine sulfate (BS) in a single oral dose for ETEC diarrhea
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 400 mg of berberine sulfate (BS) for ETEC diarrhea
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 400 mg of berberine sulfate (BS) for cholera
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 1200 mg of berberine sulfate (BS) plus tetracycline for cholera
Number of subjects: 165
Study: 2473883

Group type: EXPERIMENTAL
Intervention: New pocket-size ambulatory monitor for detecting spike and wave episodes
Number of subjects: 11

Group type: COMPARATOR
Intervention: Double-blind trial with independent scoring by 2 experienced encephalographers
Number of subjects: 11
Study: 31828956

Group type: EXPERIMENTAL
Intervention: Short-interval (≤7 weeks)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Long-interval (>7 weeks)
Number of subjects: 157
Study: 30167954

Group type: EXPERIMENTAL
Intervention: Ilaprazole 20 mg daily for 8 weeks
Number of subjects: 176

Group type: COMPARATOR
Intervention: Rabeprazole 20 mg daily for 8 weeks
Number of subjects: 176
Study: 27793818

Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin and oral ciprofloxacin for 3 days
Number of subjects: 300

Group type: COMPARATOR
Intervention: Oral ciprofloxacin and oral cefuroxime for 3 days
Number of subjects: 300
Study: 26501119

Group type: EXPERIMENTAL
Intervention: Hygiene information provided to CMV-seronegative women
Number of subjects: 646

Group type: COMPARATOR
Intervention: No hygiene information provided (comparison group)
Number of subjects: 646
Study: 23303870

Group type: EXPERIMENTAL
Intervention: Triple-fortified rice (n = 101)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Natural control rice (n = 102)
Number of subjects: 203
Study: 20805775

Group type: EXPERIMENTAL
Intervention: Airway Scope (AWS) with Manual Inline Stabilization (MIS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Airway Scope (AWS) with cervical collar immobilization
Number of subjects: 30
Study: 19640524

Group type: EXPERIMENTAL
Intervention: 22-gauge needle
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 25-gauge needle
Number of subjects: 131

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 131
Study: 17348452

Group type: EXPERIMENTAL
Intervention: Chromosome 18q allelic imbalance (AI) present
Number of subjects: 280

Group type: COMPARATOR
Intervention: No chromosome 18q allelic imbalance (AI)
Number of subjects: 280
Study: 15983311

Group type: EXPERIMENTAL
Intervention: Web-based care management
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104